NxStage Medical, Inc. (NXTM) Reports In-Line Q3 EPS, Updates Q4 and FY11 Guidance
Tweet
Share
E-mailGet Alerts NXTM Hot Sheet
Price: $30.00 --0%
Financial Fact:
Research and development: 8.28M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Research and development: 8.28M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
NxStage Medical, Inc. (NASDAQ: NXTM) reported Q3 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $55.9 million versus the consensus estimate of $53.87 million.
NxStage Medical, Inc. sees Q4 2011 EPS of $-0.10-$-0.08, versus the consensus of $-0.09. NxStage Medical, Inc. sees Q4 2011 revenue of $55.5-$56.5 million, versus the consensus of $56.2 million.
NxStage Medical, Inc. sees FY2011 EPS of $-0.43-$-0.36, versus the consensus of $-0.40. NxStage Medical, Inc. sees FY2011 revenue of $216-$217 million, versus prior guidance of $210-$215 million and the consensus of $214.39 million.
NxStage Medical, Inc. sees Q4 2011 EPS of $-0.10-$-0.08, versus the consensus of $-0.09. NxStage Medical, Inc. sees Q4 2011 revenue of $55.5-$56.5 million, versus the consensus of $56.2 million.
NxStage Medical, Inc. sees FY2011 EPS of $-0.43-$-0.36, versus the consensus of $-0.40. NxStage Medical, Inc. sees FY2011 revenue of $216-$217 million, versus prior guidance of $210-$215 million and the consensus of $214.39 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- Klarna shares tumble on weak full-year revenue guidance
- VNET Group (VNET) Misses Q2 EPS by 164c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
